Schwarz Pharma Ltd.
Records under this name other than the patents Schwarz Pharma Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,344,176 | Synthesis of substituted hydroxymethyl phenols Lapsed on the fee record Ended Jan 1, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 1, 2025 | From the USPTO record |
| US 8,299,306 | Accelerated synthesis of substituted hydroxymethyl phenols Formerly held Lapsed on the fee record Ended Oct 30, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 30, 2024 | From the USPTO record |
| US 10,251,844 | Transdermal therapeutic system and method of use thereof for treating parkinsonism Formerly held Term ended Term ended Feb 25, 2024 · From the USPTO record | Term ended | Term ended Feb 25, 2024 | From the USPTO record |
| US 8,115,028 | Shortened synthesis using paraformaldehyde or trioxane Lapsed on the fee record Ended Feb 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 14, 2024 | From the USPTO record |
| US 6,858,650 | Stable Salts of Novel Derivatives of 3,3-Diphenylpropylamines Term ended Ended no later than Jan 8, 2024 · Medium confidence | Term ended | Ended no later than Jan 8, 2024 | Medium confidence |
| US 9,186,335 | Hot melt TTS for administering rotigotine Formerly held Lapsed on the fee record Ended Nov 17, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 17, 2023 | From the USPTO record |
| US 7,985,873 | Synthesis of phenolic esters of hydroxymethyl phenols Lapsed on the fee record Ended Jul 26, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 26, 2023 | From the USPTO record |
| US 10,322,093 | Method for producing a transdermal therapeutic system which contains a D2 agonist Formerly held Term ended Term ended Sep 22, 2022 · From the USPTO record | Term ended | Term ended Sep 22, 2022 | From the USPTO record |
| US 7,632,859 | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease Lapsed on the fee record Ended Dec 15, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 15, 2021 | From the USPTO record |
| US 6,884,434 | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof Formerly held Term ended Term ended Mar 30, 2021 · From the USPTO record | Term ended | Term ended Mar 30, 2021 | From the USPTO record |